Verteporfin
- Generic Name
- Verteporfin
- Brand Names
- Visudyne
- Drug Type
- Small Molecule
- Chemical Formula
- C41H42N4O8
- CAS Number
- 129497-78-5
- Unique Ingredient Identifier
- WU713D62N9
- Background
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces hi...
- Indication
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors.
- Associated Conditions
- Subfoveal Choroidal Neovascularization (CNV)
- Associated Therapies
- -
Photoradiation with Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
- Conditions
- Interventions
- Procedure: BiopsyProcedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Endoscopic UltrasoundDrug: FluorouracilDrug: IrinotecanDrug: LeucovorinProcedure: Lymph Node BiopsyProcedure: Magnetic Resonance ImagingDrug: OxaliplatinBiological: PembrolizumabDrug: Photodynamic TherapyProcedure: Positron Emission TomographyOther: Questionnaire AdministrationDrug: Verteporfin
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 25
- Registration Number
- NCT06381154
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 39
- Registration Number
- NCT06306638
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Choroidal Blood Flow in Acute and Chronic Central Serous Chorioretinopathy
- First Posted Date
- 2022-10-21
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Helse Stavanger HF
- Target Recruit Count
- 50
- Registration Number
- NCT05589974
- Locations
- 🇳🇴
Stavanger University Hospital, Department of Ophthalmology, Stavanger, Norway
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Emory University
- Target Recruit Count
- 24
- Registration Number
- NCT04590664
- Locations
- 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy
- Conditions
- Interventions
- First Posted Date
- 2019-08-30
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Wake Forest University Health Sciences
- Registration Number
- NCT04075136
- Locations
- 🇺🇸
Wake Forest Health Sciences, Winston-Salem, North Carolina, United States
Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen
- Conditions
- Interventions
- First Posted Date
- 2018-03-08
- Last Posted Date
- 2018-03-08
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 60
- Registration Number
- NCT03459144
- Locations
- 🇨🇳
Zhongshan Ophthalmic Center, Guangzhou, Guangdong, China
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
- Conditions
- Interventions
- First Posted Date
- 2017-03-01
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- SpectraCure AB
- Target Recruit Count
- 66
- Registration Number
- NCT03067051
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇸🇪Skåne University Hospital, Malmö, Skåne, Sweden
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
- Conditions
- Interventions
- First Posted Date
- 2017-01-26
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT03033225
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
An Open Label, Phase II Trial of Continuous Low-Irradiance Photodynamic Therapy (CLIPT) Using Verteporfin (Visudyne®) for the Treatment of Cutaneous Metastases of Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Rogers Sciences Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT02939274
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Treatment of Primary Breast Cancer Using PDT
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- University College, London
- Target Recruit Count
- 12
- Registration Number
- NCT02872064
- Locations
- 🇬🇧
Royal Free Hospital, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.